In the present study, the treatment of catalpol obviously up-regulated SIRT1 level and inactivated the NF-kB and MAPK pathways in psoriasis conditions in vitro and in vivo, indicating that catalpol may improve the psoriasis-like symptoms via SIRT1 mediated anti-inflammatory effects. Here, NFKB1 is linked to psoriasis.